Krystal Biotech (NASDAQ:KRYS) Receives “Overweight” Rating from Cantor Fitzgerald

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $215.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 14.36% from the company’s previous close.

Several other research firms have also commented on KRYS. Citigroup upped their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday. Finally, Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $208.71.

Krystal Biotech Stock Up 6.7 %

Shares of NASDAQ:KRYS traded up $11.84 during trading on Thursday, hitting $188.01. 150,103 shares of the company traded hands, compared to its average volume of 245,822. The stock has a market capitalization of $5.41 billion, a price-to-earnings ratio of 105.99 and a beta of 0.84. The business’s fifty day moving average is $157.40 and its 200-day moving average is $175.17. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business’s revenue was up 116.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.30 earnings per share. On average, analysts forecast that Krystal Biotech will post 3.22 EPS for the current year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

Large investors have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter valued at $40,000. Values First Advisors Inc. acquired a new stake in Krystal Biotech during the 3rd quarter valued at $53,000. GF Fund Management CO. LTD. acquired a new stake in Krystal Biotech during the 4th quarter valued at $95,000. Huntington National Bank increased its stake in shares of Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after acquiring an additional 283 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after acquiring an additional 412 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).